| 3.03 -0.05 (-1.62%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.21  |
1-year : | 4.9 |
| Resists | First : | 3.61 |
Second : | 4.19 |
| Pivot price | 3.07 |
|||
| Supports | First : | 2.66 |
Second : | 2.21 |
| MAs | MA(5) : | 3.23 |
MA(20) : | 3.02 |
| MA(100) : | 1.8 |
MA(250) : | 1.84 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 48.9 |
D(3) : | 65.1 |
| RSI | RSI(14): 54.9 |
|||
| 52-week | High : | 4.19 | Low : | 0.91 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ENTX ] has closed above bottom band by 44.0%. Bollinger Bands are 18.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.16 - 3.18 | 3.18 - 3.19 |
| Low: | 2.97 - 2.99 | 2.99 - 3.01 |
| Close: | 3 - 3.03 | 3.03 - 3.06 |
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
Tue, 18 Aug 2026
A drug developer with 30-plus years joins Entera for a planned osteoporosis Phase 3 trial - Stock Titan
Wed, 12 Aug 2026
Entera Bio (ENTX) completes $275M Rule 506(b) private offering of shares and warrants - Stock Titan
Tue, 21 Jul 2026
Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know - Eastern Progress
Mon, 22 Jun 2026
ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally? - Yahoo Finance
Mon, 22 Jun 2026
ENTX Stock Pops As Entera Bio Showcases ENDO 2026 Pipeline - timothysykes.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 173 (M) |
| Shares Float | 121 (M) |
| Held by Insiders | 6.8 (%) |
| Held by Institutions | 34.2 (%) |
| Shares Short | 1,150 (K) |
| Shares Short P.Month | 333 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -46 % |
| Return on Equity (ttm) | -139 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -8.66 |
| PEG Ratio | 0 |
| Price to Book value | 20.19 |
| Price to Sales | 0 |
| Price to Cash Flow | -48.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|